Sphera Funds Management Ltd. Aldeyra Therapeutics, Inc. Transaction History

Sphera Funds Management Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $1.19 Million - $1.7 Million	-150,000 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$10.44 - $14.85 $1.57 Million - $2.23 Million	150,000 New	150,000 $1.7 Million
Q2 2020 Aug 13, 2020	SELL	$1.97 - $5.05 $2.11 Million - $5.4 Million	-1,069,089 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$7.14 - $9.85 $1.16 Million - $1.61 Million	-163,000 Reduced 13.23%	1,069,089 $9.65 Million
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $653,400 - $1.2 Million	90,000 Added 7.88%	1,232,089 $10.2 Million
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $2.01 Million - $4.24 Million	295,154 Added 34.85%	1,142,089 $15.8 Million
Q2 2018 Aug 13, 2018	SELL	$6.95 - $9.18 $1.13 Million - $1.49 Million	-162,196 Reduced 16.07%	846,935 $6.73 Million
Q1 2018 May 10, 2018	SELL	$6.55 - $8.9 $229,250 - $311,500	-35,000 Reduced 3.35%	1,009,131 $7.57 Million
Q3 2017 Nov 09, 2017	BUY	$3.9 - $10.8 $4.07 Million - $11.3 Million	1,044,131	1,044,131 $7.52 Million

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.